BioPharm News

Jul 30, 2015
By BioPharm International Editors
Cytovance Biologics Inc. announces development and manufacturing deal with NeuroFx for stem-cell-derived cell-free therapy for strokes.
Jul 30, 2015
By BioPharm International Editors
CMC Biologics and River Vision Development announce manufacturing agreement for RV001, a monoclonal antibody to treat Grave’s orbitopathy.
Jul 30, 2015
By BioPharm International Editors
Malvern Instruments' biophysical characterization equipment will be installed in a commercial applications laboratory in San Diego, California.
Jul 29, 2015
The Generic Pharmaceutical Association and the Biosimilars Council wrote an open letter to President Barack Obama protesting the patent protections outlined in the Trans-Pacific Partnership.
Jul 29, 2015
Financial expectations for Baxter’s biopharma solutions arm will drop 10% as the result of a client’s decision to move its manufacturing in house.
Jul 28, 2015
A broad indication for GSK’s investigational mAb mepolizumab, coupled with an upcoming FDA decision date, could give the manufacturer a competitive advantage in the biologic asthma market.
Jul 28, 2015
The broader aim of FDA's metrics initiative is to encourage quality manufacturing operations that will help avoid drug shortages.
Jul 27, 2015
Will AbbVie stave off biosimilar competitors by following Teva’s model for Copaxone?
Jul 27, 2015
By BioPharm International Editors
FDA’s quality metrics draft guidance details the types of data the agency plans to request and the quality metrics it plans to calculate.
Jul 27, 2015
A new study published in JAMA Internal Medicine found that manufacturers do not report a portion of adverse events to FDA within the federally mandated time frame of 15 days.